Overview A Study to Evaluate ACT-132577 in Healthy Subjects and in People With Severe Kidney Disease Status: Completed Trial end date: 2017-10-27 Target enrollment: Participant gender: Summary The primary purpose of this study is to investigate the fate of ACT-132577 in healthy subjects and in people with severe kidney disease Phase: Phase 1 Details Lead Sponsor: ActelionIdorsia Pharmaceuticals Ltd.